questionsmedicales.fr
États, signes et symptômes pathologiques
Processus pathologiques
Caractéristiques de la maladie
Maladie chronique
Hépatite chronique
Hépatite chronique : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hépatite chronique : Questions médicales les plus fréquentes",
"headline": "Hépatite chronique : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hépatite chronique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-22",
"dateModified": "2025-02-16",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hépatite chronique"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Maladie chronique",
"url": "https://questionsmedicales.fr/mesh/D002908",
"about": {
"@type": "MedicalCondition",
"name": "Maladie chronique",
"code": {
"@type": "MedicalCode",
"code": "D002908",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.291.500"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Hépatite B chronique",
"alternateName": "Hepatitis B, Chronic",
"url": "https://questionsmedicales.fr/mesh/D019694",
"about": {
"@type": "MedicalCondition",
"name": "Hépatite B chronique",
"code": {
"@type": "MedicalCode",
"code": "D019694",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.291.500.477.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Hépatite C chronique",
"alternateName": "Hepatitis C, Chronic",
"url": "https://questionsmedicales.fr/mesh/D019698",
"about": {
"@type": "MedicalCondition",
"name": "Hépatite C chronique",
"code": {
"@type": "MedicalCode",
"code": "D019698",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.291.500.477.750"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Hépatite D chronique",
"alternateName": "Hepatitis D, Chronic",
"url": "https://questionsmedicales.fr/mesh/D019701",
"about": {
"@type": "MedicalCondition",
"name": "Hépatite D chronique",
"code": {
"@type": "MedicalCode",
"code": "D019701",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.291.500.477.875"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Hépatite chronique",
"alternateName": "Hepatitis, Chronic",
"code": {
"@type": "MedicalCode",
"code": "D006521",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Heiner Wedemeyer",
"url": "https://questionsmedicales.fr/author/Heiner%20Wedemeyer",
"affiliation": {
"@type": "Organization",
"name": "Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hanover, Hanover, Germany."
}
},
{
"@type": "Person",
"name": "Grace Lai-Hung Wong",
"url": "https://questionsmedicales.fr/author/Grace%20Lai-Hung%20Wong",
"affiliation": {
"@type": "Organization",
"name": "Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China; State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China."
}
},
{
"@type": "Person",
"name": "Giuseppina Brancaccio",
"url": "https://questionsmedicales.fr/author/Giuseppina%20Brancaccio",
"affiliation": {
"@type": "Organization",
"name": "Infectious Diseases, Department of Molecular Medicine, University of Padua, Padua, Italy."
}
},
{
"@type": "Person",
"name": "Giovanni B Gaeta",
"url": "https://questionsmedicales.fr/author/Giovanni%20B%20Gaeta",
"affiliation": {
"@type": "Organization",
"name": "Infectious Diseases, Department of Mental and Physical Health, Campania University, Naples, Italy. Electronic address: giovannibattista.gaeta@unicampania.it."
}
},
{
"@type": "Person",
"name": "Maria Buti",
"url": "https://questionsmedicales.fr/author/Maria%20Buti",
"affiliation": {
"@type": "Organization",
"name": "Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus and Universitat Autònoma de Barcelona, Barcelona, Spain."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Flow Cytometry and Platelets.",
"datePublished": "2024-06-04",
"url": "https://questionsmedicales.fr/article/39089755",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cll.2024.04.011"
}
},
{
"@type": "ScholarlyArticle",
"name": "On-treatment platelet reactivity through the thromboxane A",
"datePublished": "2023-06-20",
"url": "https://questionsmedicales.fr/article/37338713",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11239-023-02818-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Multicenter evaluation of light transmission platelet aggregation reagents: communication from the ISTH SSC Subcommittee on Platelet Physiology.",
"datePublished": "2023-06-16",
"url": "https://questionsmedicales.fr/article/37331519",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jtha.2023.05.027"
}
},
{
"@type": "ScholarlyArticle",
"name": "Advances in Platelet-Dysfunction Diagnostic Technologies.",
"datePublished": "2024-06-17",
"url": "https://questionsmedicales.fr/article/38927117",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/biom14060714"
}
},
{
"@type": "ScholarlyArticle",
"name": "Postinjury platelet aggregation and venous thromboembolism.",
"datePublished": "2022-05-21",
"url": "https://questionsmedicales.fr/article/35444156",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/TA.0000000000003655"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "États, signes et symptômes pathologiques",
"item": "https://questionsmedicales.fr/mesh/D013568"
},
{
"@type": "ListItem",
"position": 3,
"name": "Processus pathologiques",
"item": "https://questionsmedicales.fr/mesh/D010335"
},
{
"@type": "ListItem",
"position": 4,
"name": "Caractéristiques de la maladie",
"item": "https://questionsmedicales.fr/mesh/D020969"
},
{
"@type": "ListItem",
"position": 5,
"name": "Maladie chronique",
"item": "https://questionsmedicales.fr/mesh/D002908"
},
{
"@type": "ListItem",
"position": 6,
"name": "Hépatite chronique",
"item": "https://questionsmedicales.fr/mesh/D006521"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hépatite chronique - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hépatite chronique",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-14",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hépatite chronique",
"description": "Comment diagnostiquer l'hépatite chronique ?\nQuels tests sanguins sont utilisés ?\nQu'est-ce qu'une biopsie hépatique ?\nQuels sont les signes d'hépatite chronique ?\nL'échographie est-elle utile ?",
"url": "https://questionsmedicales.fr/mesh/D006521?mesh_terms=Platelet+Function+Tests&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hépatite chronique",
"description": "Quels sont les symptômes courants ?\nLa jaunisse est-elle un symptôme ?\nPeut-on avoir des symptômes asymptomatiques ?\nLes démangeaisons sont-elles fréquentes ?\nY a-t-il des symptômes psychologiques ?",
"url": "https://questionsmedicales.fr/mesh/D006521?mesh_terms=Platelet+Function+Tests&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hépatite chronique",
"description": "Comment prévenir l'hépatite chronique ?\nLa vaccination est-elle efficace ?\nQuels comportements à risque éviter ?\nL'hygiène joue-t-elle un rôle ?\nLes tests de dépistage sont-ils importants ?",
"url": "https://questionsmedicales.fr/mesh/D006521?mesh_terms=Platelet+Function+Tests&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hépatite chronique",
"description": "Quels traitements existent pour l'hépatite chronique ?\nLes antiviraux sont-ils efficaces ?\nQuand faut-il envisager une transplantation ?\nY a-t-il des traitements naturels ?\nComment surveiller l'évolution de la maladie ?",
"url": "https://questionsmedicales.fr/mesh/D006521?mesh_terms=Platelet+Function+Tests&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hépatite chronique",
"description": "Quelles sont les complications possibles ?\nLa cirrhose est-elle réversible ?\nQuels signes indiquent une insuffisance hépatique ?\nLe cancer du foie est-il fréquent ?\nComment prévenir les complications ?",
"url": "https://questionsmedicales.fr/mesh/D006521?mesh_terms=Platelet+Function+Tests&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hépatite chronique",
"description": "Quels sont les principaux facteurs de risque ?\nL'usage de drogues augmente-t-il le risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe sexe influence-t-il le risque ?\nLes voyages à l'étranger sont-ils un risque ?",
"url": "https://questionsmedicales.fr/mesh/D006521?mesh_terms=Platelet+Function+Tests&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer l'hépatite chronique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sanguins, des échographies et parfois une biopsie hépatique."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent les marqueurs viraux, les enzymes hépatiques et les tests de fonction hépatique."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'une biopsie hépatique ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est un prélèvement de tissu hépatique pour évaluer l'inflammation et les lésions."
}
},
{
"@type": "Question",
"name": "Quels sont les signes d'hépatite chronique ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes peuvent inclure fatigue, jaunisse, douleurs abdominales et démangeaisons."
}
},
{
"@type": "Question",
"name": "L'échographie est-elle utile ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'échographie permet de visualiser des anomalies du foie et d'évaluer sa taille."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, jaunisse, douleurs abdominales et perte d'appétit."
}
},
{
"@type": "Question",
"name": "La jaunisse est-elle un symptôme ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la jaunisse se manifeste par une coloration jaune de la peau et des yeux."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes asymptomatiques ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines personnes peuvent être asymptomatiques malgré une hépatite chronique."
}
},
{
"@type": "Question",
"name": "Les démangeaisons sont-elles fréquentes ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les démangeaisons peuvent survenir en raison de l'accumulation de bile dans le sang."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes psychologiques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'anxiété et la dépression peuvent être des symptômes associés à l'hépatite chronique."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'hépatite chronique ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vaccination, l'hygiène et l'évitement des comportements à risque sont essentiels."
}
},
{
"@type": "Question",
"name": "La vaccination est-elle efficace ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la vaccination contre l'hépatite A et B est très efficace pour prévenir ces infections."
}
},
{
"@type": "Question",
"name": "Quels comportements à risque éviter ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez le partage d'aiguilles, les rapports sexuels non protégés et l'usage de drogues."
}
},
{
"@type": "Question",
"name": "L'hygiène joue-t-elle un rôle ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une bonne hygiène personnelle et alimentaire peut réduire le risque d'infection."
}
},
{
"@type": "Question",
"name": "Les tests de dépistage sont-ils importants ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage régulier est crucial pour détecter l'hépatite chronique tôt."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour l'hépatite chronique ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des antiviraux, des immunomodulateurs et des soins de soutien."
}
},
{
"@type": "Question",
"name": "Les antiviraux sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antiviraux peuvent réduire la charge virale et améliorer la fonction hépatique."
}
},
{
"@type": "Question",
"name": "Quand faut-il envisager une transplantation ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La transplantation est envisagée en cas d'insuffisance hépatique sévère ou de complications graves."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains traitements naturels peuvent aider, mais ils doivent être discutés avec un médecin."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'évolution de la maladie ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suivis réguliers avec des tests sanguins et des échographies sont nécessaires."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la cirrhose, le cancer du foie et l'insuffisance hépatique."
}
},
{
"@type": "Question",
"name": "La cirrhose est-elle réversible ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la cirrhose est une condition irréversible, mais son évolution peut être ralentie."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une insuffisance hépatique ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent confusion, saignements, jaunisse et accumulation de liquide abdominal."
}
},
{
"@type": "Question",
"name": "Le cancer du foie est-il fréquent ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le cancer du foie peut survenir chez les patients atteints d'hépatite chronique."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et un traitement approprié peuvent aider à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'infection virale, l'alcoolisme, et certaines maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "L'usage de drogues augmente-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'usage de drogues injectables augmente le risque d'hépatite chronique."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux d'hépatite peuvent augmenter le risque de développer la maladie."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains groupes de sexe peuvent avoir un risque plus élevé d'infection virale."
}
},
{
"@type": "Question",
"name": "Les voyages à l'étranger sont-ils un risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, voyager dans des régions à forte prévalence d'hépatite peut augmenter le risque d'infection."
}
}
]
}
]
}
Clinical assessment of platelet activation by flow cytometry is useful in the characterization and diagnosis of platelet-specific disorders and as a measure of risk for thrombosis or bleeding. Platele...
Pelacarsen decreases plasma levels of lipoprotein(a) [Lp(a)] and oxidized phospholipids (OxPL). It was previously reported that pelacarsen does not affect the platelet count. We now report the effect ...
Subjects with established cardiovascular disease and screening Lp(a) levels ≥60 mg per deciliter (~ ≥150 nmol/L) were randomized to receive pelacarsen (20, 40, or 60 mg every 4 weeks; 20 mg every 2 we...
Of the 286 subjects randomized, 275 had either an ARU or PRU test, 159 (57.8%) were on aspirin alone and 94 (34.2%) subjects were on dual anti-platelet therapy. As expected, the baseline ARU and PRU w...
Pelacarsen does not modify on-treatment platelet reactivity through the thromboxane A...
Light transmission aggregation (LTA) is used widely by the clinical and research communities. Although it is a gold standard, there is a lack of interlaboratory harmonization....
The primary objective was to assess whether sources of activators (mainly adenosine diphosphate [ADP], collagen, arachidonic acid, epinephrine, and thrombin receptor activating peptide6) and ristoceti...
An international multicenter study involving 28 laboratories in which we compared LTA results obtained with center-specific activators and a comparator that we supplied....
We report variability in the potency (P) of activators in comparison with the comparator. Thrombin receptor activating peptide 6 (P, 1.32-2.68), arachidonic acid (P, 0.87-1.43), and epinephrine (P, 0....
Based on these data, the establishment and adoption of simple standardization principles should mitigate variability due to activator sources. The observation of huge interindividual variability for c...
The crucial role of platelets in hemostasis and their broad implications under various physiological conditions underscore the importance of accurate platelet-function testing. Platelets are key to cl...
Posttraumatic venous thromboembolism (VTE) remains prevalent in severely injured patients despite chemoprophylaxis. Importantly, although platelets are central to thrombosis, they are not routinely ta...
We performed a secondary analysis of 133 severely injured patients from a prospective observational study investigating coagulation and inflammation (2011-2019). Platelet aggregation in response to st...
The 133 patients were severely injured (median Injury Severity Score, 25), and 14% developed VTE (all >48 hours after admission). At presentation, platelet count and PA were not significantly differen...
Severely injured patients with decreasing ex vivo measures of PA despite resuscitation have an increased risk of developing VTE. This may have implications for predicting development of VTE and for st...
Prognostic/Epidemiological; Level III....
A single-center study was conducted on 120 patients with inherited disorders of primary hemostasis followed at our hematological center. These patients presented a variety of bleeding symptoms; howeve...
Platelet refrigeration (cold storage) provides the advantages of an extended shelf life and reduces the risk of bacterial growth, compared to platelets stored at room temperature (RT). However, proces...
Triple-dose apheresis platelets were collected in 40% plasma/60% PAS-E, using the TRIMA apheresis platform, and refrigerated (2-6°C) within 8 h of collection. On day 2, one of each component was gamma...
The platelet concentration decreased by approximately 20% in all groups during 21 days of storage (p > .05). Irradiation (gamma or X-ray) did not affect platelet metabolism, and the pH was maintained ...
Gamma and X-ray irradiation do not affect the in vitro quality of platelet components stored in the cold for up to 21 days. This demonstrates the acceptability of irradiating cold-stored platelets, wh...
Based on previous success using apheresis platelets, we wanted to investigate the in vitro quality and platelet function in continuously cold-stored and delayed cold-stored platelet concentrates (PCs)...
We used a pool-and-split design to prepare 18 identical pairs of PCs. One unit was stored unagitated and refrigerated after production on day 1 (cold-stored). The other unit was stored agitated at roo...
All PCs complied with European recommendations (EDQM 20th edition). Both groups had mean platelet content >200 × 10...
Our findings suggest that PCs from IPUs are suitable for cold storage from day 1 until day 21 and delayed cold storage from day 5 until day 14....
Platelets for transfusion have a storage time of 5-7 days at 22°C-24°C, which results in a strain on the supply chain and supply shortages. We describe a novel method to extend platelet storage using ...
Apheresis platelets (APU) prepared in 65% platelet additive solution (PAS) were stored under standard conditions (SC) at 20°C-24°C to Day 5. Paired APUs were prepared with Xe and stored to Day 14 at 2...
XHC platelets were viable out to Day 14. The average pH of Day 14 platelets was 6.58, and 86% maintained some degree of swirl compared with 7.02 and 100% swirl for Day 5 SC platelets. The rate of glyc...
Platelet storage with the Xe/hyperbaric/cold method is a feasible candidate for extension of storage to 14 days based on in vitro characteristics. In vivo recovery and survival studies are indicated. ...
ADP-induced platelet activation leads to cell surface expression of several proteins, including TF (tissue factor). The role of ADP receptors in platelet TF modulation is still unknown. We aimed to as...
The effects of P2Y...
In blood from healthy subjects, stimulated in vitro by ADP, the percentage of TF...
Data show that TF expression is regulated by P2Y...